Resistance to Spindle Inhibitors in Glioblastoma Depends on STAT3 and Therapy Induced Senescence

While mitotic spindle inhibitors specifically kill proliferating tumor cells without the toxicities of microtubule poisons, resistance has limited their clinical utility. Treating glioblastomas with the spindle inhibitors ispinesib, alisertib, or volasertib creates a subpopulation of therapy induced senescent cells that resist these drugs by relying upon the anti-apoptotic and metabolic effects of activated STAT3. Furthermore, these senescent cells expand the repertoire of cells resistant to these drugs by secreting an array of factors, including TGF{beta}, which induce proliferating cells to exit mitosis and become quiescent--a state that also resists spindle inhibitors. Targeting STAT3 restores sensitivity to each of these drugs by depleting the senescent subpopulation and inducing quiescent cells to enter the mitotic cycle. These results support a therapeutic strategy of targeting STAT3-dependent therapy-induced senescence to enhance the efficacy of spindle inhibitors for the treatment of glioblastoma. Highlights* Resistance to non-microtubule spindle inhibitors limits their efficacy in glioblastoma and depends on STAT3. * Resistance goes hand in hand with development of therapy induced senescence (TIS). * Spindle inhibitor resistant glioblastomas consist of three cell subpopulations--proliferative, quiescent, and TIS--with proliferative cells sensitive and quiescent and TIS cells resistant. * TIS cells secrete TGF{beta}, which induces proliferative cells to become quiescent, thereby expanding the population of resistant cells in a spindle inhibitor resistant glioblastoma * Treatment with a STAT3 inhibitor kills TIS cells and restores sensitivity to spindle inhibitors.